前言 

完整分子量測定 ...............................................................................................02 

肽圖解析 ..........................................................................................................05 

糖型分析 ..........................................................................................................10 

終產(chǎn)品中游離小分子毒素藥物的定量 ...............................................................12 

抗體偶聯(lián)藥物的生物分析 .................................................................................13 

抗體類藥物高級結(jié)構(gòu)解析 - 氫氘交換質(zhì)譜 ........................................................13 

宿主細(xì)胞殘留蛋白的鑒定 .................................................................................15 

緒論 

Antibody–Drug Conjugates: Perspectives and Characterization ........................17 

Solving the Analytical Challenges of ADC Characterization ...............................38 

Tackling Analytical Method Development for ADCs ...........................................43 

抗體非靶向共價(jià)偶聯(lián)藥物分析 

Complete characterization of a lysine-linked antibody drug conjugate by native  LC/MS intact mass analysis and peptide mapping ...........................................51 

ADC 單抗藥物的分子質(zhì)量、氨基酸序列、糖基化位點(diǎn)以及 ADC 藥物結(jié)合位點(diǎn)鑒 定 .....................................................................................................................64 

Versatile data processing software leverages Orbitrap data for intact and sub-unit  mass analysis of protein biotherapeutics ...........................................................71 

Monoclonal Antibody and Related Product Characterization Under Native  Conditions Using a Benchtop Mass Spectrometer ............................................74 

Quick screening of intact antibody and antibodydrug conjugates with integrated  microfluidic capillary electrophoresis and mass spectrometry ...........................81 

IdeS-cleaved mAb subunit analysis with LC-HRAM-MS: a quick and accurate  comparison of biosimilar and originator biotherapeutics ....................................90 

半胱氨酸巰基偶聯(lián)（重鏈間靠非共價(jià)鍵結(jié)合）

Complete Characterization of a Cysteinelinked Antibody-Drug Conjugate  Performed on a Hybrid Quadrupole-Orbitrap Mass Spectrometer with High Mass  Range ..............................................................................................................99 

Exactive Plus EMR 高分辨質(zhì)譜儀實(shí)現(xiàn)非變性狀態(tài) ADCs 藥物的分析 .............102 

Enabling Mass Spectrometric Analysis of Intact Proteins in Native Conditions on A  Hybrid Quadrupole-Orbitrap Mass Spectrometer ............................................106

生物分析 

Quantitative Analysis of an Antibody Drug Conjugate using MSIA D.A.R.T.‘S  Technology, an Integral Part of the Universal Ligand Binding Mass Spectrometric  Immunoassay (LB-MSIA) Workflow ...............................................................109 

抗體藥物高級結(jié)構(gòu)解析 -- 氫氘交換質(zhì)譜 Characterization of Conformation of Therapeutic Antibody Aggregation with  Optimized Hydrogen/Deuterium Exchange Mass Spectrometer ....................118

Characterization of the Conformation of Therapeutic Antibody Oxidation Variants  with Optimized Hydrogen/Deuterium Exchange Mass Spectrometry .............121 

Evaluation of different Hydrogen/Deuterium Exchange data processing software  by looking at conformational changes induced by mAb aggregation .............124 

糖型分析 

A Complete Workflow Solution for Monoclonal Antibody Glycoform  Characterization Combining a Novel Glycan Column Technology and Bench-Top  Orbitrap LC-MS/MS ......................................................................................128 

宿主細(xì)胞殘留蛋白分析 

基于 nanoLC-MS/MS 建立對重組蛋白藥物中宿主細(xì)胞殘留蛋白分析方法 ....134

• 賽默飛OrbitrapAstral高分辨質(zhì)譜儀

  檢測儀器在線詢價(jià)